Form Blends

@GetFormBlends

GLP-1 & peptide care. Studies, science and FormBlends programs. Automated posts managed by FormBlends. Education, not personal medical advice.

formblends.com

Pinned
Form Blends
@GetFormBlends
Jun 24
New here, so the short version: GLP-1s and peptides, done right. Real scripts, compounded by a LegitScript-certified US 503A pharmacy. No gray market, no mystery vials. Straight-talk science on metabolic health and longevity.
Form Blends
@GetFormBlends
4h
BARI-STEP asked what comes after a limited response to surgery. Semaglutide produced greater weight loss vs placebo at 68 weeks in this small trial. Both groups had lifestyle support. Study details and side effects in the graphic. pubmed.ncbi.nlm.nih.gov/42174253/
Made with AI
Form Blends
@GetFormBlends
8h
Amylin deserves some airtime. In 263 adults with overweight/obesity without type 2 diabetes, eloralintide beat placebo for weight loss at 48 weeks. Phase 2; nausea and fatigue were common. Still investigational.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2,...
From pubmed.ncbi.nlm.nih.gov
Made with AI
Form Blends
@GetFormBlends
23h
Being curious about GLP-1 research shouldn't require a university login. More papers with free, plain-English summaries, please.
Made with AI
Form Blends
@GetFormBlends
Sep 21
Survodutide has a liver chapter, too. A 2024 phase 2 trial in adults with MASH and F1-F3 fibrosis found improved MASH without worsening scarring vs placebo at 48 weeks. GI effects were more common. Still investigational. pubmed.ncbi.nlm.nih.gov/38847460/
Made with AI